Key result
REVERSE-LVH protocol tests if sacubitril/valsartan regresses interstitial myocardial fibrosis better than valsartan in hypertension.
Why the study?
Diffuse interstitial myocardial fibrosis is key in hypertensive heart disease progression to HF, but whether ARNi regresses this fibrosis more effectively than ARB alone is unknown.
Does sacubitril/valsartan reduce CMR-derived diffuse interstitial fibrosis volume in adults with hypertension and LVH compared to valsartan?
RCT (n=80)
Open-label, blinded endpoint (PROBE)
1:1
Yes
Does sacubitril/valsartan reduce CMR-derived diffuse interstitial fibrosis volume in adults with hypertension and LVH compared to valsartan?
Answers are grounded in this paper and cite their sources.
The REVERSE-LVH trial protocol outlines a study to evaluate whether sacubitril/valsartan is superior to valsartan in regressing diffuse interstitial myocardial fibrosis in patients with hypertensive heart disease.
Background Diffuse interstitial myocardial fibrosis is a key common pathological manifestation in hypertensive heart disease (HHD) progressing to heart failure (HF). Angiotensin receptor–neprilysin inhibitors (ARNi), now a front-line treatment for HF, confer benefits independent of blood pressure, signifying a multifactorial mode of action beyond hemodynamic regulation. We aim to test the hypothesis that compared with angiotensin II receptor blockade (ARB) alone, ARNi is more effective in regressing diffuse interstitial myocardial fibrosis in HHD. Methods Role of ARNi in Ventricular Remodeling in Hypertensive LVH (REVERSE-LVH) is a prospective, randomized, open-label, blinded endpoint (PROBE) clinical trial. Adults with hypertension and left ventricular hypertrophy (LVH) according to Asian sex- and age-specific thresholds on cardiovascular magnetic resonance (CMR) imaging are randomized to treatment with either sacubitril/valsartan (an ARNi) or valsartan (an ARB) in 1:1 ratio for a duration of 52 weeks, at the end of which a repeat CMR is performed to assess differential changes from baseline between the two groups. The primary endpoint is the change in CMR-derived diffuse interstitial fibrosis volume. Secondary endpoints include changes in CMR-derived left ventricular mass, volumes, and functional parameters. Serum samples are collected and stored to assess the effects of ARNi, compared with ARB, on circulating biomarkers of cardiac remodeling. The endpoints will be analyzed with reference to the corresponding baseline parameters to evaluate the therapeutic effect of sacubitril/valsartan vs. valsartan. Discussion REVERSE-LVH will examine the anti-fibrotic potential of sacubitril/valsartan and will offer mechanistic insights into the clinical benefits of sacubitril/valsartan in hypertension in relation to cardiac remodeling. Advancing the knowledge of the pathophysiology of HHD will consolidate effective risk stratification and personalized treatment through a multimodal manner integrating complementary CMR and biomarkers into the conventional care approach. Clinical Trial Registration : ClinicalTrials.gov , identifier, NCT03553810.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2023) conducted an RCT in Hypertension and left ventricular hypertrophy (n=80). Sacubitril/valsartan vs. Valsartan (80-160 mg/day initially, titrated up to maximum 320 mg/day) was evaluated on Change in CMR-derived diffuse interstitial fibrosis volume from baseline. The REVERSE-LVH trial is a protocol designed to evaluate whether 52 weeks of sacubitril/valsartan therapy results in greater regression of diffuse interstitial myocardial fibrosis compared to valsartan in patients with hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: